<DOC>
	<DOCNO>NCT00663936</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy T-817MA AD patient treat dementia . Efficacy cognitive function , measure ADAS-cog cognitive assessment . The secondary objective study evaluate safety T-817MA activity daily live ( assessed ADCS-ADL ) AD patient take T-817MA , evaluate efficacy T-817MA AD patient overall global assessment use ADCS-CGIC .</brief_summary>
	<brief_title>Efficacy Safety T-817MA Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Male female ( postmenopausal surgically sterile ) 2 . Patients Mild moderate Alzheimer 's disease receiving Donepezil . 3 . Age 50 90 inclusive 4 . Patients must live community 5 . Patients must eligible informant study partner ( caregiver ) 6 . Patients eligible informant study partner ( caregiver ) must able read understand English . 7 . Informed consent obtain patient caregiver etc ( According protocol ) 1 . Patients clinically significant cardiac , hepatic renal impairment 2 . Patient dementia Alzheimer 's type etc ( According protocol ) 3 . Patients take drug donepezil Alzheimer 's disease , include rivastigmine ( Exelon® ) , galantamine ( Razadyne® ) , memantine ( Namenda™ ) tacrine ( Cognex® ) take within twelve ( 12 ) week Baseline Visit ( Visit 2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Alzheimer 's</keyword>
</DOC>